Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis.
• TNBC disproportionately affects younger women and exhibits significant demographic disparities.
• Limited targeted treatment options have historically defined TNBC management.

Purpose of the Study:

• To review the rising incidence and demographic disparities in TNBC.
• To discuss the molecular landscape and targeted therapy development for TNBC.
• To synthesize recent innovations and trends in TNBC diagnosis and therapy.

Main Methods:

• Literature review of recent practice-changing studies in TNBC.
• Analysis of molecular and genetic pathways implicated in TNBC.
• Evaluation of novel biomarkers and diagnostic advancements.

Main Results:

• Integration of immune checkpoint inhibitors and PARP inhibitors for specific TNBC subtypes.
• Introduction of antibody-drug conjugates as effective therapeutic options.
• Advancements in diagnostics, including machine learning and spatial transcriptomics, enable personalized medicine.

Conclusions:

• Emerging therapies and diagnostic tools are transforming TNBC treatment paradigms.
• Personalized approaches are becoming central to managing TNBC.
• Continued research is crucial for addressing TNBC heterogeneity and improving outcomes.